Last reviewed · How we verify
Experimental: RAL QD
At a glance
| Generic name | Experimental: RAL QD |
|---|---|
| Also known as | Raltegravir (RAL) 600mg Oral Tablet |
| Sponsor | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients (PHASE2, PHASE3)
- Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: